On the 22nd April 2013 the Curetis AG in Holzgerlingen announced the closing of a Series B financing round totaling EUR 12.5 million. The
financing was led by HBM Partners. Dr. Alexander Asam of HBM will join Curetis’ supervisory board. Curetis will use the proceeds for the next phase of commercial and operational growth.
Including the latest Series B financing, Curetis has raised a total of EUR 49.1 million in equity capital to date. In addition to HBM Partners, which has taken an EUR 6.0 million equity stake in Curetis, the company’s existing institutional investors aeris Capital, LSP Life Sciences Partners, Forbion Capital, BioMedInvest, Roche Venture Fund, CD Venture and KfW have contributed a total of EUR 5.6 million to the round on a pro rata basis. Curetis’ management as well as several of the company's founders, private investors and board members also co-invested.
Founded in 2007, Curetis AG is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis AG, The CE-marked Unyvero™ System, will enable the detection of a broad panel of bacteria and antibiotic resistances from a single sample in one run. It processes a disposable cartridge providing the necessary reagents to complete the analysis from sample to result.
The first CE-marked Unyvero™ Cartridge, Unyvero™ P50, focuses on pneumonia testing and simultaneously analyses 39 DNA targets. The second Unyvero™ application for implant & tissue infections is already in product development. Cartridges for additional indications, such as blood stream infections and tuberculosis, are in preparation.
Curetis will use the proceeds for the next phase of commercial and operational growth, including a prospective, multi-center FDA registrational trial with 2,000 patients and the further expansion of the company’s commercial activities and team in Europe.
Curetis anticipates a phase of rapid market adoption in the DACH region (Germany, Austria, Switzerland) where more than 50 top tier hospitals have agreed to install Unyvero™ for local testing. The inclusion of Unyvero™ in an upcoming global Phase IIb trial by Sanofi Pasteur is expected to add further momentum to the market penetration of Unyvero™.
Moreover, the company expects to continue the rapid international expansion of its commercial distribution network across Europe and the Middle East, but also towards Asia, Latin America and, following FDA clearance, tothe USA.
Further upcoming milestones include the market launch of a second Unyvero™ cartridge application (ITI) together with Heraeus Medical and clinical data from a global Phase III trial in community-acquired bacterial pneumonia conducted by Cempra Pharmaceuticals.
"We have followed Curetis' progress and development for more than 18 months and have been impressed by the team's track-record of delivering on all key clinical and commercial milestones,” said Dr. Alexander Asam, Investment Advisor at HBM Partners. “We consider Curetis Unyvero™ Solution to be a leading, world-class sample-to-answer platform. The solution offers an unrivalled combination of multiplexing pathogens and antibiotic resistance markers, paired with ease-of-use at the point of need and the ability to use any native clinical sample material."
"We are extremely pleased to have won HBM Partnersas lead investorfor our new round. With HBM joining our syndicate of investors, we are well positioned to continue executing on our clinical and commercial plans,” added Oliver Schacht, CEO of Curetis.“ Our syndicate has the breadth, depth and quality as well as financial strength to take Curetis all the way to achieveits strategic corporate objectives and to globally roll out Unyvero™ in the years ahead."